** Shares of drug developer Immunic rise 20% to $1.86 premarket
** Co says an independent data monitoring committee has recommended continuing its late-stage trial for an experimental multiple sclerosis drug without changes
** The drug, vidofludimus calcium, is being tested in patients with multiple sclerosis, a chronic autoimmune disease that affects the central nervous system
** The committee has recommended the trial is not futile and should continue as planned after an interim analysis - IMUX
** Co expects the study to be completed in 2026
** Up to last close, stock up 3.3% YTD
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。